10-K: Merck & Co. Reports Strong 2024 Performance Driven by Oncology, Issues Guidance for 2025

Merck & Co.'s 2024 annual report reveals robust sales growth driven by its oncology portfolio, particularly Keytruda, while also outlining challenges and strategic initiatives for the future.

Summary

• Merck & Co.'s 2024 sales reached $64.2 billion, a 7% increase from 2023, or 10% excluding foreign exchange impacts.
• Pharmaceutical sales were $57.4 billion, with Keytruda contributing $29.482 billion, an 18% increase.
• Gardasil/Gardasil 9 sales declined 3% to $8.583 billion due to lower demand in China.
• Animal Health sales increased 4% to $5.877 billion.
• GAAP net income attributable to Merck & Co., Inc. was $17.117 billion.
• The company anticipates a significant decline in Gardasil/Gardasil 9 sales in China for 2025 and expects U.S. sales of Keytruda to decline beginning in January 2028 due to government pricing under the IRA.
• Merck is working to mitigate the potentially harmful effects that the IRA could have, which could include a detrimental impact on innovation.
• The company is prioritizing research and development efforts, focusing on breakthrough science for unmet medical needs.
• Merck is committed to a net-zero target for its GHG emissions across its global operations (Scopes 1, 2 and 3) by 2045, aligned with the guidelines of the Science Based Targets initiative (SBTi).

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. While there's strong growth in key areas like oncology, there are also significant challenges and expected declines in sales for major products. The company is taking steps to mitigate these risks and invest in future growth, but the overall outlook is cautiously optimistic.

Positives

• Strong growth in oncology, particularly Keytruda, driving overall sales increase.
• Successful launch of Winrevair in the cardiovascular segment.
• Continued growth in Animal Health segment.
• Advancement of the company's pipeline with several regulatory submissions and Phase 3 initiations.
• Commitment to environmental sustainability with a net-zero target for GHG emissions by 2045.

Negatives

• Decline in Gardasil/Gardasil 9 sales in China.
• Expected decline in U.S. sales of Keytruda beginning in 2028 due to government pricing under the IRA.
• Loss of market exclusivity for Bridion in Europe and Japan.
• Manufacturing delays related to Varivax and ProQuad which will result in supply constraints in 2025.

Risks

• Patent rights are increasingly being challenged by competitors.
• The company faces increasing pricing pressure with respect to its products.
• Unfavorable or uncertain economic conditions could negatively affect operating results.
• The company faces intense competition from both lower cost generic and biosimilar products and competitors products.
• The company is exposed to market risk from fluctuations in currency exchange rates and interest rates.
• The company continues to be a target of cyber-attacks that could lead to a disruption of its worldwide operations.

Future Outlook

The company expects pricing pressures to continue in the future and anticipates a significant decline in Gardasil/Gardasil 9 sales in China for 2025 and expects U.S. sales of Keytruda to decline beginning in January 2028 due to government pricing under the IRA.

Industry Context

The pharmaceutical industry is highly competitive and regulated, with companies facing pressure on product pricing and market access due to global cost containment efforts and government regulations.

Comparison to Industry Standards

• The document does not provide a direct comparison of Merck's results to specific industry standards or competitors.
• However, it mentions that the company's competitors include other worldwide research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, generic drug manufacturers, and animal health care companies.
• The document also notes that the company faces intense competition from both lower cost generic and biosimilar products and competitors products.

Legal Proceedings

• The company has sued the U.S. government regarding the IRAs Program.
• The company is often involved in patent disputes relating to challenges to its patents or claims by third parties of infringement against the company.
• The company is at risk for product liability and consumer protection claims and civil and criminal governmental actions related to its products, research and/or marketing activities.

Stakeholder Impact

• Shareholders may experience fluctuations in stock value due to various factors, including competition, regulation, and economic conditions.
• Employees may be affected by restructuring activities and changes in compensation and benefits.
• Customers and patients may benefit from new product launches and expanded indications for existing products, but may also face pricing pressures and access challenges.
• Suppliers may be impacted by changes in the company's supply chain and environmental sustainability initiatives.
• Creditors may be affected by changes in the company's debt levels and financial performance.

Next Steps

• Merck is working with Daiichi Sankyo to address FDA feedback regarding patritumab deruxtecan.
• The CHMPs recommendation will now be reviewed by the EC for marketing authorization in the EU, and a final decision is expected by the second quarter of 2025.
• The company is working to mitigate the potentially harmful effects that the IRA could have, which could include a detrimental impact on innovation.
• The next government-mandated price reduction in Japan is scheduled to occur in April 2025.
• The Phase 2 study results for MK-2060 will be presented at a scientific meeting later in 2025.

Key Dates